Zdrowie i gospodarka · 15/03/2004
FDA Clears DIAZEPAM Injection for Approval via Abbreviated New Drug Applications
The FDA has determined that DIAZEPAM Injection USP (5 mg/mL in a 1-mL container) was not withdrawn from sale due to safety or effectiveness concerns, paving the way for the approval of abbreviated new drug applications for this medication.
Source: Federal Register — Food and Drug AdministrationOpen original release →